Background:
Methicillin resistance Staphylococcus aureus (MRSA) strains become a major challenge to the public health and health provider due to their wide spread and resistance to wide spectrum of antibacterial agents.
Aim:
This study aimed to characterize recombinant lysostaphin produced by Escherichia coli BL21(DE3) and to investigate the biosynthesis of silver nanoparticles (SNPs) by Candida albicans (C. albicans) against MRSA.
Methods:
Samples were collected from vaginal samples. The methods included efficient cloning, expression, and purification of recombinant lysostaphin, a potent antibacterial enzyme targeting Staphylococcus aureus (S. aureus), and achieved with advanced molecular techniques in E. coli BL21(DE3). The SNPs were synthesized using a biogenic approach with C. albicans, demonstrating stable and efficient silver ion reduction, as confirmed by UV-visible spectroscopy, Scanning Electron Microscope (SEM) and Fourier-transform infrared spectroscopy (FTIR) analyses.
Results:
The antibacterial assays against MRSA strains of S. aureus showed significant inhibition by both lysostaphin and SNPs. The combination of biosynthesized SNPs/PEG with lysostaphin exerted significant activity against tested bacteria, resulted in zone of growth inhibition 20.33 ± 0.88 mm.
Conclusion:
These findings suggest a promising synergistic antibacterial strategy, offering hope in the fight against MRSA. The study findings reveal that the lysostaphin and SNPs could be effective in the treatment of MRSA-related infections, especially when used in a combination.
Key words: Candida albicans, Nanoparticles, Mastitis, Recombinant lysostaphin, Synergestic effect
|
